By Sean Moloughney, Editor05.18.22
The U.S. Senate Health, Education, Labor, and Pensions (HELP) Committee has released a discussion draft of the Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act, which includes language to mandate product listing of dietary supplements, similar to the Dietary Supplement Listing Act of 2022 (S. 4090) introduced in April by Sen. Dick Durbin (D-IL) and Sen. Mike Braun (R-IN).
The FDASLA bill would reauthorize the Food and Drug Administration’s (FDA) prescription drug, generic drug, biosimilar, and medical device user fee agreements. These user fee programs must be reauthorized every 5 years so the bill is considered “must-pass” legislation to provide for timely review of new drug and biologic license applications. The current user fee programs are currently authorized through September 2022.
The discussion draft was released by HELP Committee Chair Senator Patty Murray (D-WA) and Ranking Member Senator Richard Burr (R-NC). The senators deve
FREE SUBSCRIPTION
Continue reading this story and get 24/7 access to Nutraceuticals World for FREE
FREE SUBSCRIPTION
